JNJ-81201887 (via Janssen)

About OmniAb

OmniAb operates as a pure-play antibody discovery platform, licensing its proprietary transgenic animal technologies to over 100 biopharmaceutical partners worldwide. Its core strategy is to generate recurring, non-dilutive revenue through upfront fees, research funding, and, most significantly, downstream milestones and royalties on partnered programs that advance into clinical development and commercialization. The company's key achievement is establishing a broad and deep partner network, with numerous programs derived from its technology now in clinical trials, validating the platform's ability to generate high-quality drug candidates.

Therapeutic Areas

Other Plaque Psoriasis Drugs